Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ibsa Pharma SAS currently holds a patent portfolio with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is being reviewed by 1 distinct examiner, CHO, DAVID H, who is also the busiest examiner with 1 busiest examiner pending action. The prosecution is concentrated within 1 distinct art unit, reflecting a narrow technical focus for the company's current USPTO filings.
Practitioners should recognize that having 1 pending office action under 1 distinct examiner creates a singular focus for the portfolio's current efforts. CHO, DAVID H is the sole individual responsible for the 1 busiest examiner pending action, meaning his specific preferences will dictate the immediate results in the Biotechnology & Pharmaceuticals area. The matching count of 1 pending office action and 1 distinct examiner within 1 distinct art unit simplifies the tracking of deadlines and examiner interviews. However, this lack of examiner variety means the company cannot test different arguments across multiple files. The outcome of this 1 pending office action will define the company's standing at the USPTO for this technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17789749 | COMPOSITION COMPRISING HYALURONIC ACID AND A POLYOL AND/OR CARBOXYMETHYL CELLULOSE | CHO, DAVID H | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17789749 | COMPOSITION COMPRISING HYALURONIC ACID AND A POLYOL AND/OR CARBOXYMETHYL CELLULOSE | CHO, DAVID H | 1693 | §112 | Final Rejection | 8d overdue | Pending | Jun 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIbsa Pharma SAS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David H Cho has the most, with 1 of Ibsa Pharma SAS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
